189 related articles for article (PubMed ID: 29882856)
1. Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.
Bosseler M; Marani V; Broukou A; Lequeux A; Kaoma T; Schlesser V; François JH; Palissot V; Berchem GJ; Aouali N; Janji B
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882856
[TBL] [Abstract][Full Text] [Related]
2. The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner.
Janji B; Vallar L; Al Tanoury Z; Bernardin F; Vetter G; Schaffner-Reckinger E; Berchem G; Friederich E; Chouaib S
J Cell Mol Med; 2010 Jun; 14(6A):1264-75. PubMed ID: 19799649
[TBL] [Abstract][Full Text] [Related]
3. Quantitative kinetic study of the actin-bundling protein L-plastin and of its impact on actin turn-over.
Al Tanoury Z; Schaffner-Reckinger E; Halavatyi A; Hoffmann C; Moes M; Hadzic E; Catillon M; Yatskou M; Friederich E
PLoS One; 2010 Feb; 5(2):e9210. PubMed ID: 20169155
[TBL] [Abstract][Full Text] [Related]
4. L-plastin Ser5 phosphorylation is modulated by the PI3K/SGK pathway and promotes breast cancer cell invasiveness.
Machado RAC; Stojevski D; De Landtsheer S; Lucarelli P; Baron A; Sauter T; Schaffner-Reckinger E
Cell Commun Signal; 2021 Feb; 19(1):22. PubMed ID: 33618712
[TBL] [Abstract][Full Text] [Related]
5. Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.
Ocio EM; Mateos MV; San-Miguel JF
Expert Opin Investig Drugs; 2012 Aug; 21(8):1075-87. PubMed ID: 22621161
[TBL] [Abstract][Full Text] [Related]
6. L-plastin Ser5 phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream of the ERK/MAPK pathway.
Lommel MJ; Trairatphisan P; Gäbler K; Laurini C; Muller A; Kaoma T; Vallar L; Sauter T; Schaffner-Reckinger E
FASEB J; 2016 Mar; 30(3):1218-33. PubMed ID: 26631483
[TBL] [Abstract][Full Text] [Related]
7. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
8. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A; Bernal-Mizrachi L; Vertino P; Sun SY; Chen J; Munshi N; Fu H; Kowalski J; Boise LH; Lonial S
Leukemia; 2018 Mar; 32(3):744-751. PubMed ID: 28924240
[TBL] [Abstract][Full Text] [Related]
10. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
13. L-plastin phosphorylation: a novel target for the immunosuppressive drug dexamethasone in primary human T cells.
Wabnitz GH; Michalke F; Stober C; Kirchgessner H; Jahraus B; van den Boomen DJ; Samstag Y
Eur J Immunol; 2011 Nov; 41(11):3157-69. PubMed ID: 21805466
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms in multiple myeloma drug resistance.
Nikesitch N; Ling SC
J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
[TBL] [Abstract][Full Text] [Related]
16. Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
Maiso P; Huynh D; Moschetta M; Sacco A; Aljawai Y; Mishima Y; Asara JM; Roccaro AM; Kimmelman AC; Ghobrial IM
Cancer Res; 2015 May; 75(10):2071-82. PubMed ID: 25769724
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the M(r) 65,000 lymphokine-activated killer proteins phosphorylated after tumor target binding: evidence that pp65a and pp65b are phosphorylated forms of L-plastin.
Frederick MJ; Rodriguez LV; Johnston DA; Darnay BG; Grimm EA
Cancer Res; 1996 Jan; 56(1):138-44. PubMed ID: 8548753
[TBL] [Abstract][Full Text] [Related]
19. Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
de la Puente P; Azab F; Muz B; Luderer M; Arbiser J; Azab AK
Leuk Lymphoma; 2016 Jul; 57(7):1677-86. PubMed ID: 26421357
[TBL] [Abstract][Full Text] [Related]
20. [Effect of rosiglitazone on the expression of HIF1α and IGF1 mRNA in myeloma].
Rui M; Fu T; Liu Y; Huang H; Fu J
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):641-4. PubMed ID: 25052610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
